Prostamax
KEDP peptide, Lys-Glu-Asp-Pro, prostate bioregulator peptide
Prostamax is marketed as a prostate-specific peptide bioregulator from the Khavinson series. Three published studies do examine this compound, but all three are chromatin and calorimetry experiments in human lymphocytes, and none touches prostate tissue or any urological outcome. One of them reports that Prostamax more than doubled sister chromatid exchange frequency, a standard marker of genomic instability, which the authors interpret favourably and which deserves a much more sceptical reading.
Mechanism
The mechanism attributed to Prostamax by sellers is the generic Khavinson model applied to prostate tissue: nuclear entry, direct promoter DNA interaction and tissue-selective transcriptional regulation, with claimed normalisation of prostatic epithelial and stromal function. No experiment supports any part of that as it applies to the prostate.
What has actually been measured is chromatin behaviour in lymphocytes. Differential scanning microcalorimetry of human lymphocytes reported that Prostamax redistributes heat between chromatin denaturation endotherms and shifts them to lower temperatures, interpreted as partial relaxation of the 30-nanometre chromatin fibre. A later cytogenetic study in cells from donors aged 75 to 86 reported reduced pericentromeric heterochromatin segments on chromosomes 1 and 9, increased silver-positive nucleolar organiser regions, and a rise in sister chromatid exchange frequency. A 2023 computational study listed KEDP among peptides predicted to be efficient ligands of the LAT and PEPT transporters. All of this is generic chromatin and transport biology, in blood cells or in silico. None of it is prostate biology.
Naming is a persistent source of confusion here. Several distinct Russian prostate preparations circulate with similar names. Prostatilen is a peptide extract of bovine prostate that has its own small clinical literature in Russian urology. Prostamol is a phytotherapeutic containing saw palmetto extract, unrelated to peptides entirely. Prostamax as sold in the peptide market is a defined synthetic tetrapeptide. Evidence attaching to one of these is routinely presented as though it applied to another, and readers should treat any citation offered for Prostamax with attention to which preparation was actually studied.
The general difficulty with the series applies with particular force to prostate tissue: prostate growth and function are dominated by androgen receptor signalling, a well-characterised pathway with well-characterised pharmacology. No account has been offered of how a four-residue peptide would intersect with it.
What the research shows
Contrary to the common claim that no research exists, three compound-specific studies are indexed, all from a Georgian and Russian collaboration and all in human lymphocytes. A 2004 Biofizika paper used microcalorimetry to show Prostamax shifts chromatin denaturation endotherms in lymphocytes in situ. A 2009 Georgian Medical News paper examined Prostamax alongside copper and cadmium ions on lymphocyte chromatin thermal stability. A 2012 Georgian Medical News paper studied cells from donors aged 75 to 86 and reported chromatin decondensation, framed by the authors as releasing genes repressed by heterochromatinisation.
That 2012 paper contains a result that should be reported prominently rather than buried. Prostamax increased sister chromatid exchange frequency from 5.9 plus or minus 0.2 per cell in intact cells to 12.0 plus or minus 0.28 per cell, and increased silver-positive nucleolar organiser regions from 0.95 to 2.5 per cell. Sister chromatid exchange is a long-established assay for genotoxic exposure and genomic instability; a more than doubling is the kind of magnitude ordinarily reported as a positive genotoxicity signal. The authors interpret it instead as evidence of beneficial chromatin decondensation. Both readings are available from the data, and a reader deciding whether to put this compound in their body should know that the strongest compound-specific finding in the entire Prostamax literature is one that, on conventional toxicological interpretation, points towards harm rather than benefit.
What does not exist is any prostate research. No study in any species has examined Prostamax in prostatic tissue, on lower urinary tract symptoms, on prostate volume, on urinary flow, or on any other urological endpoint. There is no animal work, no pharmacokinetics, no toxicology and no registered clinical trial.
The clinical context makes the evidence vacuum consequential. Lower urinary tract symptoms in older men can arise from benign prostatic hyperplasia, prostatitis or prostate cancer, and distinguishing them requires assessment. Benign prostatic hyperplasia has treatments with demonstrated effects on symptom scores and on progression to retention and surgery. Prostate cancer detected early is frequently curable. A product marketed for prostate health on no prostate evidence carries the specific risk that a man with progressive symptoms self-treats rather than being assessed, and the window in which detection matters most is exactly the asymptomatic or mildly symptomatic phase.
Evidence assessment
Preclinical only
The three compound-specific studies are ex vivo chromatin and calorimetry experiments in human lymphocytes from a single collaboration; there is no prostate data in any species, no animal work, no toxicology and no clinical trial, and one of the three reports a genomic instability signal.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro) Preclinical only
Prostamax increased sister chromatid exchange frequency from 5.9 to 12.0 per cell, increased silver-positive nucleolar organiser regions from 0.95 to 2.5 per cell, and reduced large pericentromeric heterochromatin segments on chromosomes 1 and 9. The authors interpret this as chromatin decondensation releasing repressed genes.
The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ Preclinical only
Prostamax redistributed heat between chromatin denaturation endotherms and shifted them to lower temperatures, interpreted as partial relaxation of the 30-nanometre chromatin fibre and small changes in nucleosomal organisation.
Microcalorimetric study of human blood lymphocytes culture at presence of copper, cadmium and prostamax Preclinical only
Characterised thermal denaturation of lymphocyte membrane, nuclear and cytoplasmic proteins; copper ions condensed heterochromatin while cadmium ions decondensed and partly denatured it.
Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters Preclinical only
KEDP was named among the peptides scoring most efficiently as a ligand of these transporters, leading the authors to propose transporter-mediated uptake.
Effects of short peptides on lymphocyte chromatin in senile subjects Preclinical only
Short peptides were reported to alter heterochromatin structure in lymphocytes from elderly subjects.
Safety
Uncharacterised, with one specific and under-reported signal. There is no toxicology study, no animal safety study and no human adverse event record. However, the 2012 cytogenetic study reported that Prostamax more than doubled sister chromatid exchange frequency in lymphocytes from elderly donors, from 5.9 to 12.0 exchanges per cell. Sister chromatid exchange is a conventional biomarker of genotoxic stress and genomic instability. The authors present this positively as chromatin decondensation, but the same number read against standard genetic toxicology practice is a warning, and it has never been followed up with a proper genotoxicity assessment. That is worth weighing against a compound marketed to older men, in whom prostate cancer risk is already elevated. The dominant practical risk remains delayed evaluation of lower urinary tract symptoms that warrant clinical assessment. Material sold online is unregulated and cannot be verified against a published reference standard.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No MHRA marketing authorisation. Supply for human use engages the Human Medicines Regulations 2012 regardless of a 'research use only' label. |
| United States | Not approved by the FDA, never studied under an investigational new drug application, and absent from clinical trial registries. Sold as a research chemical. |
| WADA (sport) | Not individually named on the Prohibited List but captured by section S0 (non-approved substances), prohibited at all times. |
Questions
Three studies examine the compound itself, but all are chromatin and calorimetry experiments in human lymphocytes, not prostate tissue. No study in any species has examined Prostamax in the prostate or measured any urological outcome, and there is no animal work, no toxicology and no clinical trial.
No, and one finding points the other way. The 2012 cytogenetic study reported that Prostamax more than doubled sister chromatid exchange frequency in cells from donors aged 75 to 86, from 5.9 to 12.0 per cell. Sister chromatid exchange is a standard marker of genotoxic stress. The authors read this positively as chromatin decondensation; on conventional toxicological interpretation it is a warning sign, and it has never been properly followed up.
No, and the confusion is common. Prostatilen is a bovine prostate peptide extract with its own small Russian urology literature. Prostamol is a saw palmetto phytotherapeutic containing no peptides at all. Prostamax is a synthetic tetrapeptide. Evidence for one is frequently presented as though it applied to another.
There is no evidence that it can. Nothing has been measured in prostate tissue, urinary symptoms, prostate volume or urinary flow. Lower urinary tract symptoms in older men can indicate benign prostatic hyperplasia, prostatitis or prostate cancer, and the main risk of an unevidenced product here is that it delays an assessment that distinguishes between them.